Pazopanib in Molecularly Selected Patients With Advanced NSCLC
A Pilot Study of Pazopanib in Molecularly Selected Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
Sponsor: Novartis
Terminated
Terminated by sponsor
Other terminated trials from Novartis
Other Carcinoma, Non-Small Cell Lung trials with similar outcome
Listed as NCT02193152, this PHASE2 trial focuses on Carcinoma, Non-Small Cell Lung and Non-Small Cell Lung Cancer and remains terminated or withdrawn. Sponsored by Novartis, it has been updated 17 times since 2015, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
17 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Jan 2023 — Jul 2024 [monthly]
Terminated PHASE2
-
Dec 2022 — Jan 2023 [monthly]
Terminated PHASE2
▶ Show 12 earlier versions
-
Jan 2021 — Dec 2022 [monthly]
Terminated PHASE2
-
Aug 2020 — Jan 2021 [monthly]
Terminated PHASE2
Status: Active Not Recruiting → Terminated
-
Mar 2020 — Aug 2020 [monthly]
Active Not Recruiting PHASE2
Phase: PHASE1 → PHASE2
-
Sep 2019 — Mar 2020 [monthly]
Active Not Recruiting PHASE1
-
Mar 2019 — Sep 2019 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Feb 2019 — Mar 2019 [monthly]
Recruiting PHASE1
-
Dec 2018 — Feb 2019 [monthly]
Recruiting PHASE1
-
Jun 2018 — Dec 2018 [monthly]
Recruiting PHASE1
-
Aug 2017 — Jun 2018 [monthly]
Recruiting PHASE1
-
Mar 2017 — Aug 2017 [monthly]
Recruiting PHASE1
-
Feb 2017 — Mar 2017 [monthly]
Recruiting PHASE1
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE1
First recorded
Apr 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Novartis
- Washington University School of Medicine
For direct contact, visit the study record on ClinicalTrials.gov .